S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
OTCMKTS:TRPXD

Therapix Biosciences Stock Forecast, Price & News

Add
Compare
Today's Range
N/A
50-Day Range
$4.00
$5.98
52-Week Range
N/A
Volume
900 shs
Average Volume
1,852 shs
Market Capitalization
$299 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A

Receive TRPXD News and Ratings via Email

Sign-up to receive the latest news and ratings for Therapix Biosciences and its competitors with MarketBeat's FREE daily newsletter.


About Therapix Biosciences

Therapix Biosciences Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include THX-110, which has completed Phase II a clinical trial for the treatment of Tourette syndrome and Obstructive Sleep Apnea; THX-160, which has completed two preliminary preclinical studies for the treatment of acute and chronic pain; and THX-210 for the treatment of autism spectrum disorder and epilepsy. The company was formerly known as NasVax Ltd. and changed its name to Therapix Biosciences Ltd. in November 2013. Therapix Biosciences Ltd. was founded in 2004 and is headquartered in Givatayim, Israel.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:TRPXD
CIK
N/A
Fax
N/A
Employees
8
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$0.28 per share

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$299 thousand
Optionable
Not Optionable

MarketRank

Overall MarketRank

0.00 out of 5 stars

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Therapix Biosciences (OTCMKTS:TRPXD) Frequently Asked Questions

Who are Therapix Biosciences' key executives?

Therapix Biosciences' management team includes the following people:
  • Mr. Oz Adler CPA, Chief Financial Officer (Age 33, Pay $220k)
  • Dr. Adi Zuloff-Shani, Chief Technologies Officer (Age 50, Pay $237k)
  • Mr. Amitay Weiss, CEO & Director (Age 58)

What is Therapix Biosciences' stock symbol?

Therapix Biosciences trades on the OTCMKTS under the ticker symbol "TRPXD."

How do I buy shares of Therapix Biosciences?

Shares of TRPXD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

How much money does Therapix Biosciences make?

Therapix Biosciences has a market capitalization of $0.00.

How many employees does Therapix Biosciences have?

Therapix Biosciences employs 8 workers across the globe.

What is Therapix Biosciences' official website?

The official website for Therapix Biosciences is therapixbio.com.

How can I contact Therapix Biosciences?

The company can be reached via phone at 972 3 616 7055.


This page was last updated on 1/22/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.